News

Roche also highlighted progress for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE). The ALLEGORY Phase III study, now under FDA review, showed 76.7 % of patients achieved a clinical response versus 53.5 % on placebo, a result that could lead to approval by December 2026. Gazyva/Gazyvaro generated CHF 986 million in 2025 sales, a 14 % year‑ov...

Full article

Ens­pryng’s Phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD) reached its primary endpoint, reducing the risk of a new relapse by 68 % versus placebo. At 48 weeks, 87 % of Ens­pryng recipients remained relapse‑free compared with 67 % on placebo. MRI data demonstrated a 79 % reduction in the annual...

Full article

Roche’s Phase III data on fenebrutinib and Enspryng, the company’s two front‑line neurological assets, were disclosed on Tuesday. In the FENhance 1 and 2 studies, fenebrutinib reduced the annualized relapse rate in relapsing multiple sclerosis (RMS) by 51.1 % and 58.5 % versus teriflunomide over 96 weeks, a benefit that translates to an average of...

Full article

The company, CMB.TECH NV, has published its annual report for the year ended December 31, 2025. The report is available on the company’s website and has also been filed with the U.S. Securities and Exchange Commission as Form 20‑F. Shareholders are invited to participate in the Annual General Meeting and Special General Meeting on May 21, 2026, whe...

Full article

Analyst activity has been mixed. Keefe Bruyette maintains an Outperform rating but lowered its price target to $2,300 from $2,375. Deutsche Bank downgraded FCNCA to Hold from Buy with a $2,154 target, and JPMorgan cut its target to $2,200 from $2,450, downgrading to Neutral from Overweight. The downgrades stem from concerns about the company’s SVB...

Full article

The bank’s leadership added Holt Chetwood as Regional Executive Vice President for the South Region. In this role he will oversee 55 branches across South Carolina and parts of Georgia, manage business and branch banking operations, and lead a team of over 400 associates.

Full article

First Citizens BancShares (FCNCA) will report earnings for the quarter ended March 31 2026 before the U.S. markets open on April 23. Analysts expect revenue of $2.17 billion, a 1.5 % increase from the same quarter last year, and earnings per share of $39.08, up 3.4 % year‑over‑year. The consensus efficiency ratio is 63.1 %, the net interest margin...

Full article

Organic sales grew 1.2 % YoY, offset by positive currency translation and the impact of acquisitions and divestitures. 3M launched 84 new products in the quarter, 35 % more than the previous year, and is on track to introduce 350 products in 2026, ahead of the Investor Day target of 1,000 new items through 2027. The Madison Fire & Rescue acquisitio...

Full article

The stock fell 1.3 % to $149.50 following the earnings release, reflecting a 30 % discount to an intrinsic‑value estimate of $177.32. The day of the release, the stock slipped 2 % and was the largest loser in the Dow, contributing to a 5.4 % year‑to‑date decline. Market sentiment remained mixed, with a 7.95 % rise in the CBOE Volatility Index to 18...

Full article

Strategically, 3M is expanding its data‑center footprint and has doubled manufacturing capacity for its Expanded Beam Optical interconnect technology. New heat‑dissipation solutions for electrical systems and improved interconnectors for data centers are in development. In a significant portfolio move, 3M acquired Madison Fire & Rescue from Bain Ca...

Full article